[go: up one dir, main page]

MX2019009070A - Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion. - Google Patents

Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.

Info

Publication number
MX2019009070A
MX2019009070A MX2019009070A MX2019009070A MX2019009070A MX 2019009070 A MX2019009070 A MX 2019009070A MX 2019009070 A MX2019009070 A MX 2019009070A MX 2019009070 A MX2019009070 A MX 2019009070A MX 2019009070 A MX2019009070 A MX 2019009070A
Authority
MX
Mexico
Prior art keywords
immunomodulatory therapeutic
oncogene mutation
activating oncogene
compositions encoding
therapeutic mrna
Prior art date
Application number
MX2019009070A
Other languages
English (en)
Inventor
Yi-Chun Huang Eric
LACOVELLI Jared
Mckinney Kristine
Valiante Nicholas
Wah Tse Sze-
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MX2019009070A publication Critical patent/MX2019009070A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La descripción presenta composiciones terapéuticas inmunomoduladoras de un ARNm que codifica un péptido de activación de mutaciones oncogénicas y un ARNm que codifica un polipéptido que potencia respuestas inmunitarias al péptido de activación de mutaciones oncogénicas, por ejemplo, un ARNm que codifica un inmunopotenciador. La descripción también presenta métodos para el uso de estas, por ejemplo, para estimular las respuestas inmunitarias contra el cáncer.
MX2019009070A 2017-02-01 2018-02-01 Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion. MX2019009070A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762453465P 2017-02-01 2017-02-01
US201762467063P 2017-03-03 2017-03-03
US201762490523P 2017-04-26 2017-04-26
US201762541571P 2017-08-04 2017-08-04
PCT/US2018/016510 WO2018144775A1 (en) 2017-02-01 2018-02-01 Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides

Publications (1)

Publication Number Publication Date
MX2019009070A true MX2019009070A (es) 2019-10-30

Family

ID=61244714

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009070A MX2019009070A (es) 2017-02-01 2018-02-01 Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
MX2022011934A MX2022011934A (es) 2017-02-01 2019-07-30 Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011934A MX2022011934A (es) 2017-02-01 2019-07-30 Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.

Country Status (15)

Country Link
US (3) US20190351039A1 (es)
EP (1) EP3576780A1 (es)
JP (2) JP2020514321A (es)
KR (1) KR20190110612A (es)
CN (2) CN117224710A (es)
AU (1) AU2018214556A1 (es)
BR (1) BR112019015797A2 (es)
CA (1) CA3051252A1 (es)
CL (1) CL2019002134A1 (es)
CO (1) CO2019009234A2 (es)
EA (1) EA201991804A1 (es)
IL (1) IL268361A (es)
MX (2) MX2019009070A (es)
SG (1) SG11201906969PA (es)
WO (1) WO2018144775A1 (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3981437T (lt) 2014-04-23 2025-01-10 Modernatx, Inc. Nuleorūgšties vakcinos
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017049245A2 (en) 2015-09-17 2017-03-23 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN117731769A (zh) 2015-10-22 2024-03-22 摩登纳特斯有限公司 用于水痘带状疱疹病毒(vzv)的核酸疫苗
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
RS63381B1 (sr) 2015-10-22 2022-08-31 Modernatx Inc Vakcine protiv respiratornih virusa
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
ES2924407T3 (es) 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
EP3394030B2 (en) 2015-12-22 2025-02-12 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
MA46240A (fr) 2016-09-14 2019-07-24 Modernatx Inc Compositions d'arn de haute pureté et procédés pour leur préparation
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
US11752206B2 (en) * 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
MA52262A (fr) 2017-03-15 2020-02-19 Modernatx Inc Vaccin à large spectre contre le virus de la grippe
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
DK3596042T3 (da) 2017-03-15 2022-04-11 Modernatx Inc Krystalformer af aminolipider
SMT202300097T1 (it) 2017-03-15 2023-05-12 Modernatx Inc Composto e composizioni per il rilascio intracellulare di agenti terapeutici
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
JP2021512090A (ja) * 2018-01-30 2021-05-13 モデルナティーエックス， インコーポレイテッド 免疫細胞に薬剤を送達するための組成物及び方法
KR20210018323A (ko) 2018-06-06 2021-02-17 매사추세츠 인스티튜트 오브 테크놀로지 진핵 세포에서의 번역을 위한 원형 rna
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
IL280110B2 (en) 2018-07-26 2025-07-01 Curevac Netherlands B V Cancer vaccines ready for use
JP2022500443A (ja) * 2018-09-13 2022-01-04 モデルナティーエックス， インコーポレイテッド 進行性家族性肝内胆汁うっ滞障害を処置するための修飾ｍＲＮＡ
WO2020058239A1 (en) * 2018-09-18 2020-03-26 Universiteit Gent Therapeutic nanoparticles and methods of use thereof
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
JP2022501367A (ja) 2018-09-20 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. 脂質ナノ粒子の調製及びその投与方法
TW202039534A (zh) * 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
JP2022524951A (ja) * 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
JP2022526089A (ja) 2019-03-11 2022-05-23 モデルナティエックス インコーポレイテッド 流加バッチインビトロ転写プロセス
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
WO2020237227A1 (en) 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Circular rna compositions and methods
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN114728176A (zh) * 2019-10-09 2022-07-08 川斯勒佰尔公司 信使rna的组合物、方法和使用
EP4045527A1 (en) * 2019-10-15 2022-08-24 ModernaTX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
EP4613276A3 (en) * 2019-11-12 2025-12-17 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
KR20220102617A (ko) * 2019-11-15 2022-07-20 다이이찌 산쿄 가부시키가이샤 HPV mRNA 를 봉입한 핵산 지질 입자 백신
WO2021113777A2 (en) 2019-12-04 2021-06-10 Orna Therapeutics, Inc. Circular rna compositions and methods
KR102410556B1 (ko) * 2020-01-16 2022-06-20 아주대학교산학협력단 미토콘드리아 타겟팅용 펩타이드
AU2021213812A1 (en) * 2020-01-30 2022-08-04 Modernatx, Inc. mRNAs encoding metabolic reprogramming polypeptides and uses thereof
CN111440825A (zh) * 2020-04-07 2020-07-24 嘉晨西海(杭州)生物技术有限公司 一种脂质体载mRNA的方法
PH12022553033A1 (en) * 2020-04-09 2023-06-14 Verve Therapeutics Inc Base editing of angptl3 and methods of using same for treatment of disease
TW202204622A (zh) * 2020-04-09 2022-02-01 大陸商蘇州艾博生物科技有限公司 針對冠狀病毒之核酸疫苗
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
IL297502A (en) 2020-04-24 2022-12-01 Genexine Inc A method for treating cervical cancer
EP4150079A1 (en) 2020-05-15 2023-03-22 Crispr Therapeutics AG Messenger rna encoding cas9 for use in genome-editing systems
IL300247A (en) * 2020-07-31 2023-03-01 Combined Therapeutics Inc Compositions and methods for improving vaccination
CN116322751A (zh) * 2020-08-04 2023-06-23 蛋白科技先锋 包含能够动力学控制的佐剂的mRNA疫苗
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20240026317A1 (en) * 2020-10-14 2024-01-25 Dong Shen PAN-RAS mRNA CANCER VACCINES
US20230382943A1 (en) 2020-10-20 2023-11-30 St Pharm Co., Ltd. Oligonucleotide for 5'-capped rna synthesis
AU2021381384A1 (en) * 2020-11-20 2023-06-22 Think Therapeutics, Inc. Compositions and methods for optimized peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) * 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
AU2021410666A1 (en) * 2020-12-21 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising ester-linked acetals
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
WO2022171032A1 (zh) * 2021-02-10 2022-08-18 上海吉倍生物技术有限公司 Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体
WO2022187698A1 (en) * 2021-03-05 2022-09-09 Modernatx, Inc. Vlp enteroviral vaccines
JP2024511799A (ja) * 2021-03-26 2024-03-15 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート ネオアンチゲンワクチンのための方法および化合物
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US20220364078A1 (en) 2021-05-14 2022-11-17 Crispr Therapeutics Ag Mrna large scale synthesis and purification
CN113264842B (zh) 2021-07-21 2022-03-01 苏州科锐迈德生物医药科技有限公司 一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN115703713B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
TW202325263A (zh) 2021-09-14 2023-07-01 美商雷納嘉德醫療管理公司 非環狀脂質及其使用方法
CN117440943B (zh) * 2021-10-15 2025-09-30 厦门赛诺邦格生物科技股份有限公司 含氮的阳离子脂质及其应用
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
WO2023122234A2 (en) * 2021-12-22 2023-06-29 Memorial Sloan-Kettering Cancer Center Cells expressing fas ligand and cflip polypeptides and uses thereof
CN116376942A (zh) * 2021-12-31 2023-07-04 广州国家实验室 mRNA疫苗
CN118574843A (zh) * 2022-01-21 2024-08-30 T-Knife 股份有限公司 以可检测的亲和力结合特异性肽的抗原识别构建体和对kras具有抗原特异性的t细胞受体以及相应的核酸序列、载体、宿主细胞、药物组合物和试剂盒
CR20240374A (es) * 2022-03-16 2024-10-22 Boehringer Ingelheim Int Antígenos tumorales, compuestos que comprenden los antígenos tumorales kras, tpx2 o aurka y usos de los mismos
CN115521220B (zh) * 2022-05-19 2023-06-09 仁景(苏州)生物科技有限公司 长链烷基酯胺类化合物及其制备方法和在核酸递送方面的应用
CN115286674A (zh) * 2022-06-13 2022-11-04 湖北英纳氏生物科技有限公司 一种阳离子脂质体及其制备方法
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN115869332A (zh) * 2022-10-27 2023-03-31 北京新合睿恩生物医疗科技有限公司 递送至体内后在肝脏少表达的mRNA药物及其制备方法
WO2024102332A1 (en) * 2022-11-07 2024-05-16 Himv Llc Vaccine compositions comprising a neoantigen of kras
WO2024107827A1 (en) * 2022-11-16 2024-05-23 The Broad Institute, Inc. Therapeutic exploitation of sting channel activity
CN120265312A (zh) * 2022-11-22 2025-07-04 伊利克斯根治疗公司 用于癌症免疫疗法的抗原
US20250333728A1 (en) 2022-11-24 2025-10-30 Suzhou Abogen Biosciences Co., Ltd. Utr molecule for increasing protein expression level
WO2024136608A1 (ko) * 2022-12-23 2024-06-27 한미약품 주식회사 복수 kras 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도
WO2024147556A1 (ko) * 2023-01-05 2024-07-11 의료법인 명지의료재단 K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물
EP4649087A2 (en) 2023-01-11 2025-11-19 Engage Biologics Inc. Non-viral expression systems and methods of use thereof
WO2024199359A1 (zh) * 2023-03-28 2024-10-03 江苏瑞科生物技术股份有限公司 包含环二核苷酸分子的脂质体佐剂系统及其制备方法
WO2024211447A1 (en) * 2023-04-03 2024-10-10 Chrysalis Biotherapeutics Tp508 mrnas
CN117604031B (zh) * 2023-04-20 2025-05-09 龙岩学院 一种猫冠状病毒S蛋白mRNA的体外转录系统及其构建方法
CN119330848B (zh) * 2023-10-19 2025-07-08 仁景(苏州)生物科技有限公司 用于递送的脂质化合物及脂质纳米颗粒
US20250144234A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics Inc. RNA for In vivo Transfection with Increased Expression
WO2025201437A1 (zh) * 2024-03-29 2025-10-02 仁景(苏州)生物科技有限公司 Sting蛋白突变体、编码其的核酸及其应用
WO2025206850A1 (ko) * 2024-03-29 2025-10-02 한미약품 주식회사 복수 kras 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613481D0 (en) 1986-06-04 1986-07-09 Diatech Ltd Translation of mrna
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5723332A (en) 1993-11-26 1998-03-03 British Technology Group Limited Translational enhancer DNA
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5824497A (en) 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
US6503503B1 (en) 1997-05-13 2003-01-07 Duke University Allogeneic cellular vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
US20060009633A9 (en) 1997-11-13 2006-01-12 Genset, S.A. Complementary DNAs encoding proteins with signal peptides
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
ES2240745T3 (es) 2001-06-05 2005-10-16 Curevac Gmbh Composicion farmaceutica que contiene un arnm estabilizado y optimizado para la traduccion, adecuada como vacuna y como regenerante de tejidos.
EP1430128B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
AU2002349784A1 (en) 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
US20040223949A1 (en) 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
BR0316758A (pt) 2002-12-16 2005-10-25 Globeimmune Inc Vacinas baseadas em levedura como imunoterapia
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
DK2578685T3 (da) 2005-08-23 2019-06-03 Univ Pennsylvania Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf
EP1968622B1 (en) 2006-01-05 2014-08-27 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
ES2465600T3 (es) 2006-01-05 2014-06-06 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos del páncreas
US20100286232A1 (en) 2006-03-02 2010-11-11 The Ohio State University Microrna expression profile associated with pancreatic cancer
MX2008012392A (es) 2006-03-27 2008-12-17 Globeimmune Inc Mutacion de ras, y composiciones y metodos relacionados con la misma.
AU2007299828C1 (en) 2006-09-19 2014-07-17 Interpace Diagnostics, Llc MicroRNAs differentially expressed in pancreatic diseases and uses thereof
ES2425416T3 (es) 2006-11-01 2013-10-15 The Ohio State University Research Foundation Firma de expresión del microARN para predecir la supervivencia y la metástasis en el carcinoma hepatocelular
CN101622349A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-21调节的基因和途径
US8415096B2 (en) 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
US20090099034A1 (en) 2007-06-07 2009-04-16 Wisconsin Alumni Research Foundation Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
JP2010533649A (ja) 2007-07-13 2010-10-28 ザ ジョンズ ホプキンス ユニバーシティー Ｂ７−ｄｃ改変体
AU2008281015B2 (en) 2007-07-27 2012-07-26 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumors
US8476419B2 (en) 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
AU2008329755A1 (en) 2007-11-30 2009-06-04 The Ohio State University Research Foundation MicroRNA expression profiling and targeting in peripheral blood in lung cancer
WO2009111088A2 (en) 2008-01-02 2009-09-11 The Johns Hopkins University Antitumor immunization by liposomal delivery of vaccine to the spleen
EP2260110B1 (en) 2008-02-08 2014-11-12 Asuragen, INC. miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
JP2011517932A (ja) 2008-02-28 2011-06-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト慢性リンパ球性白血病（ｃｃｌ）と関連するマイクロｒｎａシグネチャーおよびその使用
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
WO2009149539A1 (en) 2008-06-10 2009-12-17 Université de Montréal Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
US20110262485A1 (en) 2008-08-04 2011-10-27 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CN102439169B (zh) 2008-11-13 2014-11-19 复旦大学 用于结肠直肠癌的微rna表达谱分析的组合物和方法
EP2358902A1 (en) 2008-12-10 2011-08-24 Universität Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
EP2246433A1 (de) * 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
CA2761411A1 (en) 2009-05-08 2010-11-11 The Ohio State University Research Foundation Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
LT2440183T (lt) 2009-06-10 2018-08-10 Arbutus Biopharma Corporation Patobulinta lipido kompozicija
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
US20130059015A1 (en) 2010-03-11 2013-03-07 H. Lee Moffitt Cancer Center & Research Institute Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
WO2011143656A2 (en) 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
RU2671482C2 (ru) * 2010-08-31 2018-10-31 Новартис Аг Маленькие липосомы для доставки кодирующей иммуноген рнк
LT3981427T (lt) * 2010-08-31 2022-08-10 Glaxosmithkline Biologicals S.A. Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
SMT202200321T1 (it) 2010-10-01 2022-09-14 Modernatx Inc Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
EP2633034B1 (de) 2010-10-26 2017-11-29 Friedrich-Alexander-Universität Erlangen-Nürnberg NFkB-SIGNALWEG-MANIPULIERTE DENDRITISCHE ZELLEN
EP2663548B1 (en) 2011-01-11 2017-04-05 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2012151212A1 (en) 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
EP2705370A2 (en) 2011-05-06 2014-03-12 Xentech Markers for cancer prognosis and therapy and methods of use
CA2835641C (en) 2011-05-11 2019-05-28 Exosome Diagnostics, Inc. Nucleic acid extraction from heterogeneous biological materials
BR112013029490A2 (pt) * 2011-05-17 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos projetados e métodos de uso dos mesmos para vertebrados não humanos
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
RS62497B1 (sr) * 2011-05-24 2021-11-30 BioNTech SE Individualizovane vakcine protiv kancera
CN107095849A (zh) 2011-06-08 2017-08-29 夏尔人类遗传性治疗公司 可裂解脂质
JP5965481B2 (ja) 2011-07-15 2016-08-03 レオ ファーマ アクティーゼルスカブ 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の診断用マイクロｒｎａプロファイリング
EP2751292A4 (en) 2011-09-01 2015-05-20 Allegro Diagnostics Corp METHOD AND COMPOSITIONS FOR DETECTING CANCER BASED ON MIRNA EXPRESSION PROFILES
WO2013036201A1 (en) 2011-09-06 2013-03-14 Agency For Science, Technology And Research Polypeptide vaccine
WO2013066678A1 (en) 2011-10-26 2013-05-10 Georgetown University Microrna expression profiling of thyroid cancer
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
CA3018046A1 (en) * 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
CN103547683A (zh) * 2012-03-22 2014-01-29 耶鲁大学 Kras突变和肿瘤生物学
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
CN104540945A (zh) 2012-04-30 2015-04-22 格伦·N·巴伯 调节免疫应答
CA2872930A1 (en) * 2012-05-09 2013-11-14 Gradalis, Inc. Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations
CA2876150A1 (en) 2012-06-08 2013-12-12 The Johns Hopkins University Compostions and methods for cancer immunotherapy
WO2014013995A1 (ja) * 2012-07-16 2014-01-23 協和発酵キリン株式会社 KRAS遺伝子発現抑制RNAi医薬組成物
US10973892B2 (en) 2012-09-04 2021-04-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
US10093701B2 (en) 2012-09-07 2018-10-09 University Of Miami Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
EP3417874B1 (en) 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014145038A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
EP2983705A2 (en) 2013-04-10 2016-02-17 Skau Aps Use of immune suppressive peptides as adjuvants
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
ES2822584T3 (es) 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
CN105188373B (zh) 2013-05-18 2017-09-22 艾杜罗生物科技公司 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
EP3060056A4 (en) 2013-10-21 2017-10-18 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
BR112016013138A2 (pt) * 2013-12-09 2018-01-16 Targovax Asa mistura de peptídeos
EP3094342A4 (en) 2014-01-15 2017-12-27 Nikolai Khodarev Anti-tumor therapy
WO2015123532A1 (en) * 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
US9364523B2 (en) 2014-03-17 2016-06-14 Tapimmune Inc. Chimeric nucleic acid molecule with non-AUG translation initiation sequences
LT3981437T (lt) * 2014-04-23 2025-01-10 Modernatx, Inc. Nuleorūgšties vakcinos
WO2015164743A2 (en) * 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
SG11201608712PA (en) 2014-05-06 2016-11-29 Targovax Asa Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
HRP20221536T1 (hr) 2014-06-25 2023-02-17 Acuitas Therapeutics Inc. Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
EP3197490B1 (en) 2014-09-26 2023-06-21 Bavarian Nordic A/S Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
JP2018516847A (ja) 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
CA2975333A1 (en) 2015-04-22 2016-10-27 Curevac Ag Rna containing composition for treatment of tumor diseases
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US10835585B2 (en) 2015-05-20 2020-11-17 The Broad Institute, Inc. Shared neoantigens
CA2989157A1 (en) 2015-06-11 2016-12-15 University Of Miami Cancer treatment and diagnosis
US20190374628A1 (en) * 2015-06-16 2019-12-12 Targovax Asa Mutated fragments of the ras protein
EP3310384A1 (en) 2015-06-17 2018-04-25 CureVac AG Vaccine composition
MA42502A (fr) * 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017020026A1 (en) * 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017023779A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
WO2017049245A2 (en) * 2015-09-17 2017-03-23 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US10322177B2 (en) 2015-10-07 2019-06-18 Nant Holdings Ip, Llc Activation of immune-related signaling pathways in cells via optofection
MX2018004544A (es) 2015-10-12 2018-11-09 Nantomics Llc Composiciones y métodos para los neoepítopos de cáncer viral.
SG10201913547YA (en) 2015-10-19 2020-02-27 Cadila Healthcare Ltd New adjuvant and vaccine composition containing the same
CN108430456B (zh) * 2015-10-22 2022-01-18 摩登纳特斯有限公司 癌症疫苗
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3393511A1 (en) 2015-12-21 2018-10-31 La Jolla Institute for Allergy and Immunology Leveraging immune memory from common childhood vaccines to fight disease
WO2017118702A1 (en) 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
KR20180119659A (ko) 2016-03-04 2018-11-02 뉴욕 유니버시티 항종양 면역을 유도하기 위한 종양 관련 항원의 다중 에피토프를 발현하는 바이러스 벡터
WO2017177204A1 (en) 2016-04-09 2017-10-12 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
AU2017260610B2 (en) 2016-05-04 2022-10-27 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
US11078247B2 (en) 2016-05-04 2021-08-03 Curevac Ag RNA encoding a therapeutic protein
CN109890408A (zh) 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
LT3488443T (lt) 2016-07-20 2021-10-25 BioNTech SE Neoepitopų, kaip ligai specifinių taikinių, parinkimas padidinto efektyvumo terapijai
CN110418636A (zh) 2016-08-23 2019-11-05 杰罗米.J.申塔格 将肽、蛋白质和核酸负载至乳糜微粒和体细胞中的胆固醇酯囊泡
CA3042015A1 (en) * 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
EP3534943A2 (en) 2016-11-04 2019-09-11 Hookipa Biotech GmbH Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.

Also Published As

Publication number Publication date
EP3576780A1 (en) 2019-12-11
CL2019002134A1 (es) 2019-11-22
MX2022011934A (es) 2022-10-20
CN117224710A (zh) 2023-12-15
JP2023103250A (ja) 2023-07-26
US20190351039A1 (en) 2019-11-21
IL268361A (en) 2019-09-26
CN110430894A (zh) 2019-11-08
US20190175727A1 (en) 2019-06-13
JP2020514321A (ja) 2020-05-21
US20210128721A1 (en) 2021-05-06
KR20190110612A (ko) 2019-09-30
EA201991804A1 (ru) 2020-02-07
SG11201906969PA (en) 2019-08-27
AU2018214556A1 (en) 2019-08-15
BR112019015797A2 (pt) 2020-03-17
US10881730B2 (en) 2021-01-05
CO2019009234A2 (es) 2019-08-30
WO2018144775A1 (en) 2018-08-09
CA3051252A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
MX2019009070A (es) Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
CL2021001744A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
HK1245080A1 (zh) 自然杀伤细胞的方法和组合物
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
ZA202204223B (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
EP4599893A3 (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
CL2019001002A1 (es) Métodos y composiciones para inmunoterapia por tusc2.
AR108688A1 (es) Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
MX2021004453A (es) Nuevos antigenos y metodos contra el cancer.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite
MX376830B (es) Peptido derivado de koc1 y vacuna que lo incluye.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
EP3848383A3 (en) Urlc10-derived peptide and vaccine containing same
EP4282883A3 (en) Cdca1-derived peptide and vaccine containing same
EA202092271A1 (ru) Комбинации макролидных соединений и ингибиторов контрольных точек иммунитета
UY35730A (es) Composiciones farmacéuticas comprendiendo kisspeptin o sus derivados